Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer-Reference-Cited by-同舟云学术

Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer

Published:2016-12-17 Issue:4 Volume:8 Page:6057-6066
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wilkerson Paul M¹,Dedes Konstantin J¹²,Samartzis Eleftherios Pierre²,Dedes Ioannis²,Lambros Maryou B¹,Natrajan Rachael¹,Gauthier Arnaud¹,Piscuoglio Salvatore³,Töpfer Chantal¹,Vukovic Vesna¹,Daley Frances¹,Weigelt Britta³,Reis-Filho Jorge S¹³

Affiliation:

1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK

2. Department of Gynaecology, University Hospital of Zurich, 8091 Zurich, CH

3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes;Cancers;2024-09-03

2. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma;Journal of Experimental & Clinical Cancer Research;2023-10-07

3. Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma;Frontiers in Oncology;2021-10-19

4. Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer;Expert Opinion on Pharmacotherapy;2021-07-26

5. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?;Annals of Translational Medicine;2020-12